This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: High-flow nasal cannula (HFNC) is commonly used to provide respiratory support to pediatric patients with respiratory failure. Although the use of bronchodilators via HFNC has been described, the feasibility and safety of aerosolized bronchodilator delivery via HFNC are controversial. In this study, we sought to evaluate whether the HFNC system can be used to deliver nebulized bronchodilators at lower gas flow of 2–4 L/min, increase patient comfort, and minimize respiratory therapist (RT) bedside time when compared to traditional interfaces.
METHODS: A retrospective chart review of all pediatric subjects who were admitted to the pediatric ICU in a tertiary care children’s hospital and required nebulized bronchodilators between December 2017 and June 2018.
RESULTS: A total of 205 nebulizations were administered to 28 children; 31% of nebulized bronchodilators were given using a nebulization system integrated into the HFNC. Nebulized treatments resulted in an average increase in heart rate of 9.98 (95% CI 3.72–16.2) beats/min when HFNC was used and 0.64 (95% CI −1.65 to 2.93) beats/min when traditional interfaces were used, a difference of 9.34 (95% CI 2.30–16.4) beats/min (P < .001). RT bedside time was significantly longer for HFNC nebulized treatments (P = .031). Subjective level of comfort was not statically different when nebulized bronchodilators were delivered via HFNC or via traditional interfaces. Length of pediatric ICU stay was not statistically different between subjects who received some aerosol nebulized bronchodilators via HFNC versus those who received all bronchodilators through traditional interfaces (P = .11).
CONCLUSIONS: Aerosol bronchodilator delivery using HFNC is feasible at low gas flow (ie, 2–4 L/min). However, the use of HFNC did not improve subjects’ comfort, and it increased RT bedside time. Further prospective randomized studies are needed to determine the efficacy and efficiency of aerosol therapy delivered through HFNC and potential patient-oriented outcomes.
Footnotes
- Correspondence: Awni M Al-Subu MD, Division of Pediatric Critical Care, Department of Pediatrics, 600 Highland Ave, Room H6/535 CSC, Madison, WI 53792. E-mail: al-subu{at}pediatrics.wisc.edu
The authors have disclosed no conflicts of interest.
- Copyright © 2020 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Log in using your username and password
